Drug intelligence / Profile preview

Xulin Jiangu

Development stage: Phase 1
Lead developer: Fujian Academy of Traditional Chinese Medicine
Administration: Oral

Overview

Xulin Jiangu is a Traditional Chinese Medicine (TCM) granule formulation developed by the Fujian Academy of Traditional Chinese Medicine. It is primarily indicated for the treatment of postmenopausal osteoporosis, specifically in patients exhibiting the TCM syndrome of kidney deficiency and blood stasis. The formulation is designed to improve bone mineral density and alleviate symptoms associated with bone loss by addressing systemic imbalances according to TCM principles. Clinical studies have evaluated Xulin Jiangu granules in comparison to standard therapies like calcitriol to assess its efficacy in bone metabolism and safety for long-term use.

Brand names: Xulin Jiangu granules
Other names: Xulin Jiangu granules

Beyond the preview

Go deeper on Xulin Jiangu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xulin Jiangu.

Explore the full profile